
Overview
MultiQure is a life sciences company developing therapies for rare genetic neurodegenerative disorders. Its work includes the RNAi gene therapy MQ-201, which targets Huntington’s disease, and the company is preparing for clinical development. Its therapeutic portfolio also includes immuno-oncology.
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 29 days early. All were audited by a statutory auditor.
- 202513/07/2026
- 202414/07/2025
- 202304/07/2024
- 202231/05/2023
- 202130/06/2022
- 202006/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 1.40
- High
- PLN 1.40
- Low
- PLN 1.36
- Volume
- 256.73K
- Avg. vol.
- 247.94K
- Market cap
- PLN 307.02M
- P/E ratio
- –
- EPS
- -PLN 12.58
- Shares outstanding
- 225.75M
- 52-week
- PLN 1.36 – 1.50
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLPRBLG00010
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 1.55m | USD -217.99k | USD -39.98m |
| Q1 2026 | USD 7.83k | USD -458.13k | USD -606.16k |
| Q4 2025 | USD 5.78k | USD -334.76k | USD -639.88k |
| Q3 2025 | USD 66.05k | USD -227.02k | USD -305.12k |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

multiQure sees strong interest in partnering talks

multiQure partners with Granzer Regulatory Consulting & Services, an experienced regulatory adviser in gene therapy

multiQure CEO Filip Jeleń bought company shares worth PLN 100 thousand

multiQure signs letter of intent with Prof. Mirosław Ząbek, lead European surgeon of uniQure's breakthrough project
Industry
Offer
- RNAi therapies
- Huntington’s disease therapy
- Immuno-oncology therapies
Websites
The site is available in: Polish and English.
- multiqure.comHome page – multiQureWordPress 3.7Google AnalyticsGoogle Tag ManagerMeta PixelYoast SEONginx
Authorized Representatives
Manner of representation
The company is represented as follows: a) in the case of a one-person management board, the President of the Management Board is authorised to make declarations of will on behalf of the company independently; b) in the case of a multi-member management board, two members of the management board acting jointly, or one member of the management board acting jointly with a commercial proxy, are authorised to make declarations of will on behalf of the company.
Supervisory board
Beneficial owners
Multiqure is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
BIO Animali sp. z o.o. | 4,051.86 USD | 15% |
Bank accounts
Was a VAT taxpayer from 2010-08-01 to 2026-08-20.
Reason for removal: Art. 96 ust. 9a pkt 2 (VAT returns not filed for 3 consecutive months or a quarter)
Debt
1 closed proceeding recorded in KRZ history.
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| Jun 30, 2025 | Petition to declare entrepreneur bankruptcy | Closed |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Oct 30, 2025 | Commercial Companies Code notice | |
| Jul 17, 2025 | Liquidation opened | |
| Jul 9, 2025 | Call to creditors | |
| Jul 9, 2025 | Call to creditors | |
| Jul 9, 2025 | Call to creditors |
Public aid
26 public aid cases recorded, with a total value of $29,993,841.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 7, 2023 | Aid for research and development projects: experimental development | –– | Prezes Agencji Badań Medycznych | |
| Mar 7, 2023 | Aid for research and development projects: industrial research | –– | Prezes Agencji Badań Medycznych | |
| Jan 20, 2023 | Aid for research and development projects: industrial research | –– | Prezes Agencji Badań Medycznych |
European Funds
10 projects co-financed from European Funds recorded, with total EU co-financing of $29,606,776.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-07-01 | Development of a bispecific antibody fragment for simultaneous tumor control and recruitment of immune system cells (BIKE) | $7.3M$7,303,601 | Operational Programme Smart Growth | |
| 2019-07-01 | Development of a bispecific antibody fragment for simultaneous cancer treatment and recruitment of immune system cells [PHASE II] | $761.5K$761,498 | European Funds for a Modern Economy | |
| 2019-05-01 | Development of a first-in-class therapeutic medical device for use in the treatment of myasthenic crisis in patients with myasthenia gravis | $2.8M$2,806,191 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Biotechna S.A. | $2,472,888.07 | bsbiotechna.com | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com | ||
| Bioceltix S.A. | $616,315.97 | bioceltix.com | ||
| Famicordtx S.A. | $589,673.84 | famicordtx.com | ||
| VET Cell Tech sp. z o.o. | $483,439.81 | vetcelltech.com | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Vasa Therapeutics sp. z o.o. | $363,111.30 | vasatherapeutics.com | ||
| Explorna Therapeutics sp. z o.o. | $304,662.00 | explorna.com | ||
| Nanoexpo sp. z o.o. | $121,837.52 | nanoexpo.eu | ||
| Personather sp. z o.o. | $47,478.47 | personather.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-08-04 | Share capital increase (816,314.40 PLN → 22,574,931.90 PLN) | |
| 2026-08-04 | Name change (Pure Biologics → Multiqure) | |
| 2025-10-15 | Share capital increase (408,157.20 PLN → 816,314.40 PLN) | |
| 2025-03-24 | Share capital increase (397,046.10 PLN → 408,157.20 PLN) | |
| 2025-01-10 | Share capital increase (374,823.90 PLN → 397,046.10 PLN) |
FAQ
Last updated: 2026-08-27